Combination of Ranibizumab and Targeted Laser Photocoagulation

Inclusion Criteria: * Diagnosis of macular edema due to central retinal vein occlusion foveal thickness \> 250 μm (measured by OCT) * Age \> 18 years * Written informed consent of the patient * BCVA score in the study eye between 24 letters (20/320) and 78 letters (20/25) measured in ETDRS chart * History of CRVO no longer than 6 months * Presence of capillary non-perfusion in peripheral retina larger than 5 disc areas documented in ultra wide-field fluorescein angiography * Ability and willingness to attend all scheduled visits and assessments Exclusion Criteria: * CRVO with ischemic maculopathy defined as diameter of the foveolar avascular zone larger than 2 optic disc diameters * Macular edema due to another etiology than retinal vein occlusion (e.g. diabetic maculopathy, uveitis, age related macular degeneration, Irvine-Gass syndrome) * History of idiopathic central serous chorioretinopathy * Presence of vitreoretinal interface disease (e.g. vitreomacular traction, epiretinal membrane), either on clinical examination or in OCT * An eye that, in the investigator's opinion, would not benefit from resolution of macular edema, such as eyes with foveal atrophy, dense pigmentary changes, or dense subfoveal hard exudates * Aphakia in the study eye * Scatter laser photocoagulation or macular photocoagulation in the study eye prior to study entry * Intraocular or periocular injection of steroids in the study eye prior to study entry * Previous use of an anti-VEGF drug in the study eye * Cataract surgery or any other intraocular surgery in the study eye within 3 months prior to study entry * Uncontrolled glaucoma (defined as intraocular pressure ≥ 30 mm Hg despite treatment with maximal anti-glaucoma medications) * History of stroke, myocardial infarction, transient ischemic attacks within 3 months prior to the study * Pregnancy (positive urine pregnancy test) or lactation * The presence of active malignancy, including lymphoproliferative disorders. * History of allergy to fluorescein or any component of the ranibizumab formulation * Active intraocular infection * Participation in another simultaneous interventional medical investigation or trial * Women with child bearing potency without effective contraception (i. e. implants, injectables, combined oral contraceptives, some IUDs or vasectomised partner) during the conduct of the trial.